Vera kidney drug Trutakna shows strong final results in Phase 3 trial

Trutakna reduced the risk of IgA nephropathy progression by 76% in the final analysis of the ORIGIN 3 Phase 3 trial. This reduction was observed in patients receiving atacicept‑vymj over a two‑year period, stabilizing eGFR and halting disease advance. The study tracked kidney function over two years, showing that eGFR remained stable while disease markers did not worsen. Industry outlets noted the significance of the result. hcplive.com highlighted the 76% risk cut, while Yahoo Finance detailed that the drug maintained kidney function and prevented further decline across two years.

FirstWord Pharma described the data as positioning Trutakna for full regulatory approval, and STAT called the final results strong. The positive readout also came as Vera’s share price rebounded after a prior slump linked to heightened competition with Vertex, according to Investor's Business Daily. The findings matter for patients with IgA nephropathy, a condition lacking effective therapies, and for Vera Therapeutics, which aims to translate the data into a market‑ready product. Investors saw the news reverse a prior chart dip, reflecting renewed confidence.

The company is preparing to advance the drug toward full approval, guided by the positive Phase 3 outcomes. The data set the stage for an upcoming approval filing.